15542-37-7

Basic information

• Product Name: 2,4-Pentadienoic acid, 5-(4-methoxyphenyl)-, (E,E)-
• CAS NO: 15542-37-7
• Molecular Formula: C12H12O3
• Molecular Weight: 204.225
• Mol File: 15542-37-7.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 2,4-Pentadienoic acid, 5-(4-methoxyphenyl)-, (E,E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Pentadienoic acid, 5-(4-methoxyphenyl)-, (E,E)-(15542-37-7)
• EPA Substance Registry System: 2,4-Pentadienoic acid, 5-(4-methoxyphenyl)-, (E,E)-(15542-37-7)

Safety Data

• Hazardous Substances Data: 15542-37-7(Hazardous Substances Data)

Upstream product

• 49678-07-1 (2E,4E)-5-(4-methoxyphenyl)penta-2,4-dienal 
• 17171-08-3 methyl (2E,4E)-5-((p-methoxy)phenyl)penta-2,4-dienoate 
• 91-22-5 quinoline 
• 6342-88-7 (4-methoxy-cinnamylidene)-malonic acid 
• 108-24-7 acetic anhydride 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 79-10-7 acrylic acid 
• 37746-78-4 4-bromo-trans-crotonic acid ethyl ester 
• 123-11-5 4-methoxy-benzaldehyde 
• 504-31-4 pyran-2-one 
• 22980-23-0 2-oxa-3-oxobicyclo[2.2.0]hex-5-ene 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 1374313-51-5 1-(4-methoxyphenyl)allyl but-3-enoate 
• 51410-44-7 1-(4-methoxylphenyl)-2-propen-1-ol 

Downstream Products

• 66110-15-4 (2E,4E)-5-(4-methoxyphenyl)-1-(piperidine-1-yl)penta-2,4-dien-1-one 
• 406725-25-5 (2E,4E)-6-[5-(4-Methoxyphenyl)penta-2,4-dienoylamino]hexanoic acid methyl ester 
• 261913-02-4 (2E,4E)-5-(4-methoxyphenyl)-1-(4-methylpiperazine-1-yl)penta-2,4-dien-1-one 
• 120554-69-0 (E,E)-5-(4-methoxyphenyl)-2,4-pentadienoic acid 4-nitrophenyl ester 
• 443360-66-5 5t-(4-methoxy-phenyl)-penta-2t,4-dienoyl chloride 
• 17171-08-3 methyl (2E,4E)-5-((p-methoxy)phenyl)penta-2,4-dienoate 

Relevant articles and documents

(2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE

The present application relates to a novel pentadienoyl compound and a pharmaceutical composition including the same. The pentadienoyl compound of the present application may be used to prevent or treat fatty liver and fatty liver-related disease by inhibiting lipogenesis and lipid accumulation in cells and activating lipid metabolism. In addition, the pentadienoyl compound of the present application may increase a SIRT1 expression level in cells or SIRT1 activity, and thus may be used to prevent or treat a SIRT1-mediated disease. In addition, the pentadienoyl compound of the present application may reduce a CK2 expression level in cells or CK2 activity, and thus may be used to prevent or treat a CK2-mediated disease.

Catalytic Regio- and Enantioselective Alkylation of Conjugated Dienyl Amides

A method for catalytic asymmetric alkylation of conjugated dienyl amides has been developed and it allows efficient and high-yielding transformations of a wide range of polyconjugated amides into the corresponding chiral products. Smooth addition of organomagnesium reagents to relatively unreactive dienyl amides with excellent 1,6- and 1,4-selectivities, as well as enantioselectivites above 90 %, is achieved owing to the complementary action of the Lewis acid and a chiral copper-based catalyst.

Carbamic acid compounds comprising an amide linkage as hdac inhibitors

This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.